UNITED STATES SECURITIES AND EXCHANGE COMMISSION July 30, 2008

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Immunex Corp.

File No. 000-12406 - CF# 22255

Amgen Inc. (acquirer of Immunex Corp.) submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information Immunex Corp. excluded from the Exhibits to a Form 8-K filed on July 1, 1998.

Based on representations by Amgen Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.1 through June 30, 2013

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Patti J. Dennis Chief, Office of Disclosure Support